Cargando…
Molecular Characterization of Gastric Carcinoma: Therapeutic Implications for Biomarkers and Targets
Palliative chemotherapy is the mainstay of treatment of advanced gastric carcinoma (GC). Monoclonal antibodies including trastuzumab, ramucirumab, and pembrolizumab have been shown to provide additional benefits. However, the clinical outcomes are often unpredictable and they can vary widely among p...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874689/ https://www.ncbi.nlm.nih.gov/pubmed/29522457 http://dx.doi.org/10.3390/biomedicines6010032 |
_version_ | 1783310210670002176 |
---|---|
author | Kankeu Fonkoua, Lionel Yee, Nelson S. |
author_facet | Kankeu Fonkoua, Lionel Yee, Nelson S. |
author_sort | Kankeu Fonkoua, Lionel |
collection | PubMed |
description | Palliative chemotherapy is the mainstay of treatment of advanced gastric carcinoma (GC). Monoclonal antibodies including trastuzumab, ramucirumab, and pembrolizumab have been shown to provide additional benefits. However, the clinical outcomes are often unpredictable and they can vary widely among patients. Currently, no biomarker is available for predicting treatment response in the individual patient except human epidermal growth factor receptor 2 (HER2) amplification and programmed death-ligand 1 (PD-L1) expression for effectiveness of trastuzumab and pembrolizumab, respectively. Multi-platform molecular analysis of cancer, including GC, may help identify predictive biomarkers to guide selection of therapeutic agents. Molecular classification of GC by The Cancer Genome Atlas Research Network and the Asian Cancer Research Group is expected to identify therapeutic targets and predictive biomarkers. Complementary to molecular characterization of GC is molecular profiling by expression analysis and genomic sequencing of tumor DNA. Initial analysis of patients with gastroesophageal carcinoma demonstrates that the ratio of progression-free survival (PFS) on molecular profile (MP)-based treatment to PFS on treatment prior to molecular profiling exceeds 1.3, suggesting the potential value of MP in guiding selection of individualized therapy. Future strategies aiming to integrate molecular classification and profiling of tumors with therapeutic agents for achieving the goal of personalized treatment of GC are indicated. |
format | Online Article Text |
id | pubmed-5874689 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-58746892018-03-29 Molecular Characterization of Gastric Carcinoma: Therapeutic Implications for Biomarkers and Targets Kankeu Fonkoua, Lionel Yee, Nelson S. Biomedicines Review Palliative chemotherapy is the mainstay of treatment of advanced gastric carcinoma (GC). Monoclonal antibodies including trastuzumab, ramucirumab, and pembrolizumab have been shown to provide additional benefits. However, the clinical outcomes are often unpredictable and they can vary widely among patients. Currently, no biomarker is available for predicting treatment response in the individual patient except human epidermal growth factor receptor 2 (HER2) amplification and programmed death-ligand 1 (PD-L1) expression for effectiveness of trastuzumab and pembrolizumab, respectively. Multi-platform molecular analysis of cancer, including GC, may help identify predictive biomarkers to guide selection of therapeutic agents. Molecular classification of GC by The Cancer Genome Atlas Research Network and the Asian Cancer Research Group is expected to identify therapeutic targets and predictive biomarkers. Complementary to molecular characterization of GC is molecular profiling by expression analysis and genomic sequencing of tumor DNA. Initial analysis of patients with gastroesophageal carcinoma demonstrates that the ratio of progression-free survival (PFS) on molecular profile (MP)-based treatment to PFS on treatment prior to molecular profiling exceeds 1.3, suggesting the potential value of MP in guiding selection of individualized therapy. Future strategies aiming to integrate molecular classification and profiling of tumors with therapeutic agents for achieving the goal of personalized treatment of GC are indicated. MDPI 2018-03-09 /pmc/articles/PMC5874689/ /pubmed/29522457 http://dx.doi.org/10.3390/biomedicines6010032 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Kankeu Fonkoua, Lionel Yee, Nelson S. Molecular Characterization of Gastric Carcinoma: Therapeutic Implications for Biomarkers and Targets |
title | Molecular Characterization of Gastric Carcinoma: Therapeutic Implications for Biomarkers and Targets |
title_full | Molecular Characterization of Gastric Carcinoma: Therapeutic Implications for Biomarkers and Targets |
title_fullStr | Molecular Characterization of Gastric Carcinoma: Therapeutic Implications for Biomarkers and Targets |
title_full_unstemmed | Molecular Characterization of Gastric Carcinoma: Therapeutic Implications for Biomarkers and Targets |
title_short | Molecular Characterization of Gastric Carcinoma: Therapeutic Implications for Biomarkers and Targets |
title_sort | molecular characterization of gastric carcinoma: therapeutic implications for biomarkers and targets |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5874689/ https://www.ncbi.nlm.nih.gov/pubmed/29522457 http://dx.doi.org/10.3390/biomedicines6010032 |
work_keys_str_mv | AT kankeufonkoualionel molecularcharacterizationofgastriccarcinomatherapeuticimplicationsforbiomarkersandtargets AT yeenelsons molecularcharacterizationofgastriccarcinomatherapeuticimplicationsforbiomarkersandtargets |